We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
Anti-infective drug development company Appili Therapeutics is set to receive funding to support the development of a new antibiotic to treat gram-negative infections.